Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 143

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 143
---
 in National Instrument 45-106 Prospectus Exemptions (NI 45-106), and in Ontario, as defined in subsection
73.3(1) of the Securities Act (Ontario) as supplemented by the definition in NI 45-106, and are permitted clients, as defined in National
Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must
be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities
laws. Any securities sold in Canada will be subject to a hold period and will contain the following wording “Unless permitted under
securities legislation, the holder of this security must not trade the security before [insert the date that is 4 months and a day after the distribution date]”.

Securities legislation in
certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including
any amendment or supplement thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised
by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars
of these rights or consult with a legal advisor.

European Economic Area.
In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive, or a Relevant Member State,
an offer to the public of any securities may not be made in that Relevant Member State, except that an offer to the public in that Relevant
Member State of any securities may be made at any time under the following exemptions under the Prospectus Directive, if they have been
implemented in that Relevant Member State:

| ● | to any legal entity which is a qualified investor as defined in the Prospectus Directive; |

| ● | to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010                                      
 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted 
 under the Prospectus Directive, subject to obtaining the prior consent of the representatives for any such offer; or                       |

| ● | in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such                               
 offer of securities shall result in a requirement for the publication by us or any